Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice

Rheumatology

Volumn 48, Issue 9, 2009, Pages 1029-1035

  Elewaut, Dirk ^a   Matucci Cerinic, Marco ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Ankylosing spondylitis; Biologic therapy; Extra articular manifestation; Quality of life; Tumour necrosis factor

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ADALIMUMAB; AMYLOID A PROTEIN; AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYTOTOXIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOGLOBULIN A; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE ACETATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT;

AMYLOIDOSIS; ANKYLOSING SPONDYLITIS; AORTA VALVE REGURGITATION; BONE DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CREATININE CLEARANCE; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDICATION; EMPHYSEMA; ENTERITIS; GLOMERULONEPHRITIS; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; IRIDOCYCLITIS; IRITIS; KIDNEY DYSFUNCTION; LUNG ALVEOLITIS; LUNG DISEASE; LYMPHOCYTOSIS; MEDICAL PRACTICE; OSTEOPENIA; OSTEOPOROSIS; PHOTOPHOBIA; PHYSIOTHERAPY; PRIORITY JOURNAL; PSORIASIS; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOLOGY; TOPICAL TREATMENT; UVEITIS; WELLBEING; DRUG ANTAGONISM; QUALITY OF LIFE;

ANTIRHEUMATIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; QUALITY OF LIFE; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS, ANTERIOR;

EID: 70349786726     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep146     Document Type: Review

References (116)

1. Sieper J, Rudwaleit M, Khan MA, Braun J. Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol 2006;20:401-17.
2. Khan MA. Update on spondyloarthropathies. Ann Intern Med 2002;136:896-907.
3. Braun J, Bollow M, Remlinger G et al. Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
4. Brandt J, Bollow M, Haberle J et al. Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology 1999;38:831-6.
5. Gran JT, Hisby G, Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population in Tromsø, northern Norway. Ann Rheum Dis 1985;44:359-67.
6. Saraux A, Guedes C, Allain J et al. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. J Rheumatol 1999;26:2622-7.
7. Vander Cruyssen B, Ribbens C, Boonen A et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 2007;66:1072-7.
8. Van der Linden S, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals: a comparison of relatives in spondylitis patients with the general population. Arthritis Rheum 1984;27:241-9.
9. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002;61(Suppl. 3):iii8-18.
10. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003;23:61-6.
11. Calin A. Ankylosing spondylitis. Clin Rheum Dis 1985;11:41-60.
12. Bollow M, Fischer T, Reisshauer H, Sieper J, Hamm B, Braun J. T cells and macrophages predominate in early and active sacroiliitis as detected by magnetic resonance imaging in spondyloarthropathies. Ann Rheum Dis 2000;59:135-40.
13. Laloux L, Voisin MC, Allain J et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001;60:316-21.
14. Braun J, Bollow M, Neure L et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
15. van der Heijde D, Dijkmans B, Geusens P et al. Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group: efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
16. Davis JC Jr, van der Heijde DM, Braun J et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346-52.
17. Brandt J, Khariouzov A, Listing J et al. Six-month results of a double-blind, placebocontrolled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
18. van der Heijde D, Kivitz A, Schiff MH et al. ATLAS Study Group: efficacy and safety of adalimumab in patients with ankylosing spondylitis. Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54: 2136-46.
19. Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006;54:569-78.
20. Van der Linden SM, Valkenburg HA, Cats A. Evaluation of the diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
21. Braun J, Sieper J. The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol 1996;8:275-87.
22. Lee J-H, Jun J-B, Jung S et al. Higher prevalence of peripheral arthritis among ankylosing spondylitis patients. J Korean Med Sci 2002;17:669-73.
23. Resnick D. Radiology of seronegative spondyloarthropathies. Clin Orthop Relat Res 1979;143:38-45.
24. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
25. Lipsky PE, van der Heijde DM, St Clair EW et al. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group: infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
26. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000;43: 495-505.
27. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004;34:585-92.
28. Brophy S, Calin A. Ankylosing spondylitis: interaction between genes, joints, age at onset, and disease expression. J Rheumatol 2001;28:2283-8.
29. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51.
30. Meuwissen SG, Dekker-Saeys SJ, Agenant D, Tytgat G. Ankylosing spondylitis and inflammatory bowel disease. I. Prevalence of inflammatory bowel disease in patients suffering from ankylosing spondylitis. Ann Rheum Dis 1978;37:30-2.
31. Mielants H, Veys EM, Cuvelier C, De Vos M, Botelberghe L. HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis. J Rheumatol 1985;12:294-8.
32. Grillet B, deClerk L, Decker J, Rutgeerts P, Geboes K. Systematic ileocolonoscopy and bowel biopsy study in spondylarthropathy. Br J Rheumatol 1987;26:338-40.
33. Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppäalä K. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 1994; 37:23-31.
34. Bergfeldt L, Edhag O, Vedin L, Vallin H. Ankylosing spondylitis: an important cause of severe disturbances of the cardiac conduction system: prevalence among 223 pacemaker-treated men. Am J Med 1982;73:187-91.
35. Vilar MJ, Cury SE, Ferraz MB, Sesso R, Astra E. Renal abnormalities in ankylosing spondylitis. Scand J Rheumatol 1997;26:19-23.
36. Jones DW, Mansell MA, Samuell CT, Isenberg DA. Renal abnormalities in ankylosing spondylitis. Br J Rheumatol 1987;26:341-5.
37. Sampaio-Barros PD, Cerqueira EM, Rezende SM et al. Pulmonary involvement in ankylosing spondylitis. Clin Rheumatol 2007;26:225-30.
38. El Maghraoui A, Chaouir S, Abid A et al. Lung findings on thoracic high-resolution computed tomography in patients with ankylosing spondylitis. Correlations with disease duration, clinical findings and pulmonary function test. Clin Rheumatol 2004;23:123-8.
39. Souza AS Jr, Müller NL, Marchiori E, Soares-Souza LV, de Souza Rocha M. Pulmonary abnormalities in ankylosing spondylitis: aspiratory and expiratory highresolution CT findings in 17 patients. J Thorax Imaging 2004;19:259-63.
40. Inkle NA, Goole F, Nair B, Inkle N. Bone and stone in ankylosing spondylitis: osteoporosis and urolithiasis. Clin Rheumatol 2006;25:667-70.
41. Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J. Bone loss is detected more frequently in patients with ankylosing spondylitis and syndesmophytes. J Rheumatol 2005;32:1290-8.
42. Chorus AMJ, Miedema HS, Boonen A, van der Linden SJ. Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 2003;62:1178-84.
43. Hajj-Ali RA, Lowder C, Mandell BF. Uveitis in the internist's office: are a patient's eye symptoms serious? Cleve Clin J Med 2005;72:329-39.
44. Rosenbaum JT. Acute anterior uveitis, and spondyloarthropathies. Rheum Dis Clin North Am 1992;18:143-51.
45. Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987;103:234-5.
46. Smith JR, Rosenbaum JT. Management of uveitis: a rheumatologic perspective. Arthritis Rheum 2002;46:309-18.
47. Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol 1997;115:61-4.
48. Paiva ES, Macaluso DC, Edwards A, Rosenbaum JT. Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis 2000;59:67-70.
49. Santos Lacomba M, Marcos Martín C, Gallardo Galera JM et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 2001;33:251-5.
50. De Smet MD. RESCU participants. Infliximab for uveitis: forty six week efficacy and safety results from the Remicade European Study for Chronic Uveitis (RESCU). Invest Ophthalmol Vis 2006;47: E-Abstract, 1525.
51. Guignard S, Gossec L, Salliot C et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondyloarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631-4.
52. ®) inhibits uveitis flares in patients with ankylosing spondylitis (AS). Ann Rheum Dis 2008;67(Suppl. II):515.
53. Mielants H, Veys EM, Cuvelier C, De Vos M. Course of gut inflammation in spondyloarthropathies and therapeutic consequences. Baillieres Clin Rheumatol 1996;10:147-64.
54. Mielants H, Veys EM, Cuvelier C et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 1995;22:2279-84.
55. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999;10:387-98.
56. Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 2008;205:331-7.
57. Jacques P, Elewaut D. Joint expedition: linking gut inflammation to arthritis. Mucosal Immunol 2008;1:364-71.
58. Turkcapar N, Toruner M, Soykan I et al. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol Int 2006;26:663-8.
59. Braun J, Baraliakos X, Listing J et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639-47.
60. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53:1-16.
61. ® (infliximab) summary of product characteristics (SPC). Leiden. The Netherlands: Centocor B.V., 2008.
62. ® prescribing information. Malvern. PA: Centocor, Inc., 2007.
63. ® (adalimumab) summary of product characteristics (SPC). Kent, UK: Abbott Laboratories, Ltd, 2008.
64. ® (prescribing information). North Chicago, IL: Abbott Laboratories, 2008.
65. Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121:1088-94.
66. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003;62:74-6.
67. ® (prescribing information). Smyrna, GA: UCB, Inc., 2008.
68. ®) therapy improves inflammatory bowel disease (IBD) and psoriasis (PS) in patients with ankylosing spondylitis (AS). Ann Rheum Dis 2008;67(Suppl. II):623.
69. Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002;61:298-304.
70. Shaikh S. Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment. J Can Chiropr Assoc 2007;51:249-60.
71. Edmunds L, Elswood J, Kennedy LG, Calin A. Primary ankylosing spondylitis, psoriatic and enteropathic spondyloarthropathy: a controlled analysis. J Rheumatol 1991;18:696-8.
72. Sariyaka S, Basaran A, Tekin Y, Ozdolap S, Ortancil O. Is osteoporosis generalized or localized to central skeleton in ankylosing spondylitis? J Clin Rheumatol 2007;13:20-4.
73. Jun JB, Joo KB, Her TH et al. Femoral bone mineral density is associated with vertebral fractures in patients with ankylosing spondylitis: a cross-sectional study. J Rheumatol 2006;33:1637-41.
74. Gratacós J, Collado A, Pons F et al. Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 1999;42:2319-24.
75. Maillefert JF, Aho LS, El Maghraoui A, Dougados M, Roux C. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteopor Int 2001;12:605-9.
76. Visvanathan S, van der Heijde D, Deodhar A et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:175-82.
77. Bergfeldt L. HLA-B27-associated cardiac disease. Ann Intern Med 1997;127: 621-9.
78. O'Neill TW, Bresnihan B. The heart in ankylosing spondylitis. Ann Rheum Dis 1992;51:705-6.
79. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
80. Heeneman S, Daemen MJAP. Cardiovascular risks in spondyloarthritides. Curr Opin Rheumatol 2007;19:358-62.
81. Spanakis E, Sidiropoulos P, Papadakis J et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006;33:2440-6.
82. van Eijk IC, Peters MJ, Serne EH et al. Microvascular function is impaired in ankylosing spondylitis and improves after TNF{alpha} blockade. Ann Rheum Dis 2009;68:362-6.
83. Zorab PA. The lungs in ankylosing spondylitis. Q J Med 1962;31:267-81.
84. Şenocak Ö, Manisali M, Ö zaksoy D, Sevinç C, Akalin E. Lung parenchyma changes in ankylosing spondylitis: demonstration with high resolution CT and correlation with disease duration. Eur J Radiol 2003;45:117-22.
85. Kchir MM, Mtimet S, Kochbati S et al. Bronchoalveolar lavage and transbronchial biopsy in spondyloarthropathies. J Rheumatol 1992;19:913-16.
86. Gratacós J, Orellana C, Sanmarti R et al. Secondary amyloidosis in ankylosing spondylitis. A systematic survey of 137 patients using abdominal fat aspiration. J Rheumatol 1997;24:912-15.
87. Emili Gómez-C E, Sanmartí R, Solé M, Cañete JD, Muñoz-GJ. The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum 2001;44:66-72.
88. Kobak S, Oksel F, Kabasakal Y, Doganavsargil E. Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol 2007;26:2191-4.
89. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002;359:1187-93.
90. Reich K, Nestle FO, Papp K et al. EXPRESS study investigators: infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74.
91. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005;52:1227-36.
92. Baeten D, De Keyser F, Mielants H, Veys EM. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2002;16:537-49.
93. Mielants H, Sieper J, Antoni A, Van den Bosch F, van Vollenhoven RF. A new treatment paradigm in the management of spondyloarthropathies. Rheumatol News Int 2005;(Suppl. 1):1-11.
94. Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26.
95. Furst DE, Khanna D, McMahon M. Are there differences among TNF blocking agents? Reumatologia 2003;19:121-4.
96. Evans TJ, Moyes D, Carpenter A et al. Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 1994;180:2173-9.
97. Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden SJ, Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002;61 (Suppl. III):iii40-50.
98. Dougados M. Treatment of spondyloarthropathies. Recent advances and prospects in 2001. Joint Bone Spine 2001;68:557-63.
99. Dougados M, Caporal R, Doury P et al. A double blind cross over placebo controlled trial of ximoprofen in ankylosing spondylitis. J Rheumatol 1989;16:1167-9.
100. Dougados M, Béhier JM, Jolchine I et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001;44:180-5.
101. Dougados M, Nguyen M, Caporal R et al. Ximoprofen in ankylosing spondylitis. Scand J Rheumatol 1994;23:243-8.
102. Calin A, Grahame R. Double-blind crossover trial of flurbiprofen and phenylbutazone in ankylosing spondylitis. Br Med J 1974;4:494-9.
103. Tannenbaum H, De Coteau WE, Esdaile JM. A double blind multicentre trial comparing prioxicam and indomethacin in ankylosing spondylitis with long-term follow-up. Curr Ther Res 1984;36:425-35.
104. Sturrock RD, Hart FD. Double-blind crossover comparison of indomethacin, flurbiprofen and placebo in ankylosing spondylitis. Ann Rheum Dis 1974;33:129-31.
105. Moreland LW, Russel AS, Paulus HE. Management of rheumatoid arthritis: the historical context. J Rheumatol 2001;28:1431-52.
106. Wanders A, van der Heijde D, Landewe R et al. Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756-65.
107. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. ASAS Working Group: First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
108. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005;52:1000-8.
109. Zochling J, van der Heijde D, Burgos-Vargas R et al. 'Assessment in AS' international working group; European League Against Rheumatism. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
110. Braun J, Deodhar A, Dijkmans B et al. Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008;59:1270-8.
111. Baraliakos X, Listing J, Brandt J, Rudwaleit M, Sieper J, Braun J. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005;7:R439-44.
112. Baraliakos X, Listing J, Brandt J et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology 2007;46:1450-3.
113. Zhang X, Aubin JE, Inman RD. Molecular and cellular biology of new bone formation: insights into the ankylosis of ankylosing spondylitis. Curr Opin Rheumatol 2003;15:387-93.
114. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115:1571-9.
115. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70.
116. Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008;67:1276-81.